99 results
Page 2 of 5
6-K
EX-99.1
kmdcdd1ls591c05au92c
6 Jul 23
Current report (foreign)
6:18am
6-K
4mdpiu g6cia
28 Jun 23
Current report (foreign)
6:02am
6-K
EX-99.1
nfw azgjp1ru4h
23 Jun 23
Current report (foreign)
6:13am
6-K
0ey qrpuihsp
9 Jun 23
Current report (foreign)
6:03am
6-K
vn2j7zfxelz50p
1 Jun 23
Current report (foreign)
6:02am
6-K
EX-99.1
ydgv93ru9hjm7z
30 May 23
Current report (foreign)
6:19am
6-K
EX-99.1
f264tu
30 May 23
Current report (foreign)
6:11am
6-K
h2c10d
17 May 23
Current report (foreign)
6:02am
6-K
9io6y5kvn0
11 May 23
Current report (foreign)
6:10am
6-K
f0x4ga
11 May 23
Current report (foreign)
6:07am
6-K
o4q2wuuvtx0356s s1
30 Mar 23
Current report (foreign)
6:19am
6-K
EX-99.1
uuezndx c1be3
21 Dec 22
Current report (foreign)
6:01am
6-K
tgalfj8xs1 3ib
21 Dec 22
Current report (foreign)
6:01am
6-K
rxx9h44jkwzvm6x5kau8
13 Dec 22
Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics
7:00am
6-K
EX-99.1
bl8gyw
13 Dec 22
Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics
7:00am
6-K
ybf5m4
8 Dec 22
Current report (foreign)
6:46am
6-K
EX-99.1
7bd0y4
30 Nov 22
Current report (foreign)
6:28am
6-K
8bp3ym
14 Oct 22
Current report (foreign)
7:36am
6-K
fqw498d
4 Oct 22
Current report (foreign)
6:06am